Home Users Are Catalyst for Patient Monitoring Device Market

Posted by Laurie L. Sullivan

Aug 25, 2016 10:00:00 AM

Remote patient monitoring is drawing keen interest in the market for patient monitoring devices (PMDs). According to projections by BCC Research, the PMD market will grow from nearly $16.9 billion in 2015 to almost $23.8 billion in 2020, reflecting a five-year compound annual growth rate (CAGR) of 7.1%. Last year, hospitals were the largest segment of the PMD end-user market, representing 51% of the total end-user market. But in terms of growth, home users are the fastest-growing end-user segment. The market for glucose monitoring and other devices that enable patient self-monitoring at home is expected to grow during BCC Research’s forecast period.


Topics: Life Sciences, Healthcare

In Space, No One Can Hear You Bio-Print Human Organs

Posted by Clayton Luz

Aug 24, 2016 10:00:00 AM

Two high-tech companies have teamed up to develop a 3-D bio-printer capable of manufacturing human organs and tissues in orbit. The joint effort could result in the ability to manufacture transplantable organs in space for patients on earth, and help enable long-duration human exploration of deep space.

Topics: Advanced Materials

The Brave New Applications of PCR Technology

Posted by Laurie L. Sullivan

Aug 23, 2016 10:00:00 AM

Technological advances are yielding different types of polymerase chain reaction (PCR) techniques. BCC Research reveals in a new analysis that the use of PCR technology continues to expand into nonconventional applications, producing solid growth in the global market. PCR allows DNA sequencing, as well as the production of millions of copies of a specific DNA sequence, within minutes. As a result, PCR technology has helped make molecular diagnosis easier and faster. It is used frequently to diagnose disease, identify bacteria and viruses, and aid forensic investigations. And, so much more.


Topics: Life Sciences, Biotechnology

Biosimilar Therapies for Rheumatoid Arthritis Win Favor of FDA Panel

Posted by Laurie L. Sullivan

Aug 22, 2016 10:30:00 AM

The race is on to get biosimilar versions of the rheumatoid arthritis (RA) treatments Humira, the world’s top-selling drug, and Enbrel, also in the top five, to market. Companies are simultaneously defending their own biologic treatments and developing biosimilars. Case in point: Last month, Amgen floated on a recommendation from an FDA panel to approve its alternative to AbbVie’s Humira. But the following day, Novartis’ Sandoz division won similar support for FDA approval of a biosimilar to Amgen’s Enbrel. The landscape is changing fast, as companies both vie to protect their blockbusters and try to chip away at their competitor’s market share.

All transactions on our web site are PayPal verified. All major cards accepted. No PayPal account needed.
Connect with BCC